Search research articles
Contact Us
Filters
Showing results (51-60 of 129) with videos related to
Page
of 13
Sort By:
International Journal of Molecular Medicine
|
March 7, 2025
MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction
Huijun Zhou, Han Gong, Xiaohui Zeng, et al.
ACS Materials Au
|
November 18, 2024
High-Entropy Alloys in Catalysis: Progress, Challenges, and Prospects
Liang Sun, Kaihua Wen, Guanjie Li, et al.
Journal of Infection and Public Health
|
April 16, 2023
Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis
Chongqing Tan, Xia Luo, Zhen Zhou, et al.
Frontiers in Cell and Developmental Biology
|
March 11, 2020
Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients
Mulin Feng, Xiaohui Zeng, Qiujuan Su, et al.
BMJ Open
|
November 27, 2020
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Qiao Liu, Xia Luo, Liubao Peng, et al.
Food Chemistry
|
September 13, 2014
Astaxanthin is responsible for antiglycoxidative properties of microalga Chlorella zofingiensis
Zheng Sun, Jin Liu, Xiaohui Zeng, et al.
Frontiers in Public Health
|
June 11, 2025
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov's model-based evaluation
Juan Hong, Xiaohui Zeng, Wenjun Chen, et al.
Materials (Basel, Switzerland)
|
July 2, 2021
A Review on Cement Asphalt Emulsion Mortar Composites, Structural Development, and Performance
Hussaini Abdullahi Umar, Xiaohui Zeng, Xuli Lan, et al.
Clinical Therapeutics
|
May 21, 2019
Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer From the US and Chinese Perspectives
Yingjie Zhang, Xiaohui Zeng, Haijun Deng, et al.
Plos One
|
November 15, 2021
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
Qiao Liu, Chongqing Tan, Lidan Yi, et al.
Page
of 13
Search research articles
Search
Showing results (51-60 of 129) with videos related to
Sort By:
Page
of 13
International Journal of Molecular Medicine
|
March 7, 2025
MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction
Huijun Zhou, Han Gong, Xiaohui Zeng, et al.
ACS Materials Au
|
November 18, 2024
High-Entropy Alloys in Catalysis: Progress, Challenges, and Prospects
Liang Sun, Kaihua Wen, Guanjie Li, et al.
Journal of Infection and Public Health
|
April 16, 2023
Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis
Chongqing Tan, Xia Luo, Zhen Zhou, et al.
Frontiers in Cell and Developmental Biology
|
March 11, 2020
Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients
Mulin Feng, Xiaohui Zeng, Qiujuan Su, et al.
BMJ Open
|
November 27, 2020
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Qiao Liu, Xia Luo, Liubao Peng, et al.
Food Chemistry
|
September 13, 2014
Astaxanthin is responsible for antiglycoxidative properties of microalga Chlorella zofingiensis
Zheng Sun, Jin Liu, Xiaohui Zeng, et al.
Frontiers in Public Health
|
June 11, 2025
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer: a Markov's model-based evaluation
Juan Hong, Xiaohui Zeng, Wenjun Chen, et al.
Materials (Basel, Switzerland)
|
July 2, 2021
A Review on Cement Asphalt Emulsion Mortar Composites, Structural Development, and Performance
Hussaini Abdullahi Umar, Xiaohui Zeng, Xuli Lan, et al.
Clinical Therapeutics
|
May 21, 2019
Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer From the US and Chinese Perspectives
Yingjie Zhang, Xiaohui Zeng, Haijun Deng, et al.
Plos One
|
November 15, 2021
Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
Qiao Liu, Chongqing Tan, Lidan Yi, et al.
Page
of 13